Q/c Technologies, Inc. QCLS
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2014 · data as of November 13, 2026
Q/c Technologies, Inc. (QCLS) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.1, a 5-year average ROIC of -81%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.
About Q/c Technologies
Q/c Technologies is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2014. Revenue went from $4M in 2014 to $2M in 2019, a decline of about 18.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 12863% over three years (dilution for shareholders).
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $2M | $2M | $3M | $3M |
| Net income | -$12M | -$23M | -$4M | -$15M | -$30M | -$9M | -$4M | -$11M | -$7M | -$3M |
| Free cash flow | -$11M | — | — | — | — | — | — | -$9M | -$5M | -$4M |
| EPS (diluted) | $-1.73 | $-216.17 | $-103.38 | $-227.71 | $-16.49 | $-12.08 | $-30.82 | $-108.12 | $-687.89 | $-540.61 |
| Net margin | — | — | — | — | — | — | -246.6% | -651.4% | -219.6% | -111.6% |
| ROIC | -35.8% | -82.0% | -108.9% | -81.4% | -95.6% | — | — | -116.0% | -69.2% | -77.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Q/c Technologies’s P/E ratio?
About 0.1, based on the last twelve months of diluted earnings per share.
Is Q/c Technologies stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Q/c Technologies pay a dividend?
Not currently.
Is Q/c Technologies a good stock to buy?
We do not give buy or sell advice. Q/c Technologies scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.